达沙替尼and 胆红素单抗 active for ph-positive ALL in adults
(HealthDay)—Chemotherapy-free induction 和 consolidation first-line treatment with dasatinib 和 胆红素单抗 is associated with a high incidence of 分子反应 和 survival in adults with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), according to a study published in the Oct. 22 issue of the 新英格兰医学杂志.
Robin Foà, M.D., from Sapienza University of Rome, 和 colleagues conducted a single-group phase 2 trial of first-line therapy in newly diagnosed Ph-positive ALL. Sixty-three adults received dasatinib plus glucocorticoids followed by two cycles of 胆红素单抗.
研究人员发现98％ 耐心 had complete remission. Twenty-nine percent of the 耐心 had a 分子反应 at the end of dasatinib induction (day 85), 和 this increased to 60 percent after two cycles of 胆红素单抗; a further increase in the percentage of 耐心 with a 分子反应 occurred after additional 胆红素单抗 cycles. Overall survival was 95 percent 和 无病生存 中位随访期为18个月，为88％。患有 IKZF1 deletion plus additional genetic aberrations had lower 无病生存. In six 耐心 who had increased minimal residual disease during induction therapy, ABL1 mutations were detected; all were cleared by 胆红素单抗. There were six relapses 和 21 adverse events of grade 3 要么 higher. Twenty-four 耐心 received a stem cell allograft 和 one death was associated with transplantation.
"This combination was associated with high incidences of complete hematologic response 和 分子反应 并在18个月的生存期中表现出色。”